Your browser doesn't support javascript.
loading
Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.
Chen, Wenmin; Lin, Jietao; Yang, Ting; Xin Zhang, Ze; Tao, Lanting; Xiao, Zhiwei; Chen, Hanrui; Qi, Xiangjun; Sun, Lingling; Cao, Yang; Lin, Lizhu.
Afiliación
  • Chen W; Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Lin J; Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, China.
  • Yang T; Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Xin Zhang Z; Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Tao L; Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Xiao Z; Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, China.
  • Chen H; Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, China.
  • Qi X; Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Sun L; Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, China.
  • Cao Y; Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, China.
  • Lin L; Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, China.
Integr Cancer Ther ; 22: 15347354221151147, 2023.
Article en En | MEDLINE | ID: mdl-36710490

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Integr Cancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Integr Cancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article País de afiliación: China